SREBF2–STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis

Sorafenib resistance limits its survival benefit for treatment of hepatocellular carcinoma (HCC). Cholesterol metabolism is dysregulated in HCC, and its role in sorafenib resistance of HCC has not been fully elucidated. Aiming to elucidate this, in vitro and in vivo sorafenib resistant models were e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Xuetian, Kong, Youzi, Zhang, Yankun, Sun, Min, Liu, Shuyue, Wu, Zhuanchang, Gao, Lifen, Liang, Xiaohong, Ma, Chunhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899602/
https://www.ncbi.nlm.nih.gov/pubmed/35642354
http://dx.doi.org/10.1111/cas.15449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899602/
https://www.ncbi.nlm.nih.gov/pubmed/35642354
http://dx.doi.org/10.1111/cas.15449

Ejemplares similares